ArticleCancers2019
Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells.International journal of molecular sciences · 2026Article
- Article
- 3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation.ACS applied materials & interfaces · 2024Article
- DPY19L3 promotes vasculogenic mimicry by itsOncology research · 2024Article
- Article
- Risk of secondary tumours in patients with non-metastatic and metastatic human retinoblastoma.Eye (London, England) · 2023Article
- Molecular docking appraisal ofIn silico pharmacology · 2023Article
- Targeting Breast Cancer Stem Cells.International journal of biological sciences · 2023Review
- Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide.International journal of molecular sciences · 2022Article
- JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2022Article
- Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype.Journal of personalized medicine · 2022Article
- Akt Isoforms: A Family Affair in Breast Cancer.Cancers · 2021Review
- Effect of Nanog overexpression on the metastatic potential of a mouse melanoma cell line B16-BL6.Molecular and cellular biochemistry · 2021Article
- Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Targeting the Roots of Recurrence: New Strategies for Eliminating Therapy-Resistant Breast Cancer Stem Cells.Cancers · 2020Article
- Extracellular Vesicles as Drug Delivery Systems in Cancer.Pharmaceutics · 2020Review
- AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma.Respiratory research · 2020Article
- EMT related circular RNA expression profiles identify circSCYL2 as a novel molecule in breast tumor metastasis.International journal of molecular medicine · 2020Article
- Ultrasound Microbubble-Mediated microRNA-505 Regulates Cervical Cancer Cell Growth via AKT2.Analytical cellular pathology (Amsterdam) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be sustained by the presence of cancer stem cells (CSC) within a tumor. The difficulty in targeting this subpopulation derives from their dynamic interconversion process, where CSC can differentiate to non-CSC, which in turn de-differentiate into cells with CSC properties. Using fluorescent CSC models driven by the expression of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.